Blood disorders have overtaken cancer as most common therapeutic area being targeted by drugs on the European Medicines Agency's PRIME scheme for the priority review of medicines for unmet medical need.
A gene therapy that uniQure is developing for severe hemophilia B has become the latest product to make it on...